Session Details

Chair:

• Lindsay Davies, PhD, FHEA, NextCell Pharma, Sweden

Speakers:

• Dominique Farge, MD, PhD, Université Paris-Cité, AP-HP, France - The Use of MSC for the Treatment of Scleroderma
• Lindsay Davies, PhD, FHEA, NextCell Pharma, Sweden - Mesenchymal stromal cells - an interventive approach to the treatment of type 1 diabetes
• Damian García Olmo, MD, PhD, Autonomous University of Madrid, Spain - MSCs in Perianal Crohn's Disease as a paradigm of the clinical trial process in Advanced Therapies

Mesenchymal stromal cells have been employed widely for their immunomodulatory potential. This concurrent session will provide an overview of the application of these cells in the clinic for three different indications.

Session Objectives

1. An appreciation of the wide application of mesenchymal stromal cells for the treatment of different clinical indications.
2. An understanding of current practices in mesenchymal stromal cell clinical research.